Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery - 25 Nov 2016

Dong Zhi, Gao Jing, Gong Jifang, Li Jie, Li Yan, Wang Xicheng, Li Yanyan, Shen Lin, Li Jian

Abstract excerpt

OBJECTIVE: To evaluate the feasibility of imatinib reintroduction in gastrointestinal stromal tumor(GIST) with high recurrence risk after imatinib adjuvant therapy failure. METHODS: Clinical and follow-up data of 24 recurrent GIST patients with high recurrence risk receiving imatinib standard dose reintroduction(400 mg/d or 600 mg/d) after stopping imatinib adjuvant treatment more than 3 months in Department of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Neoplasm Recurrence, Local

Share to Piperazines

Share to Pyrimidines

Source

Identifiers

PMID: 27928801

Genes

PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].PMID 27928801Read ↗

Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective studySemantic proximity Read ↗

Benefit of imatinib adjuvant therapy for patients with intermediate risk gastrointestinal stromal tumor: a multi-center retrospective analysis in ChinaSemantic proximity Read ↗

Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.Semantic proximity Read ↗

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.Semantic proximity Read ↗

[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].Semantic proximity Read ↗

Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.Semantic proximity Read ↗

Adjuvant therapy of gastrointestinal stromal tumors (GIST).Semantic proximity Read ↗

The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor.Semantic proximity Read ↗

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.Semantic proximity Read ↗

[Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].Semantic proximity Read ↗

Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?Semantic proximity Read ↗

Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.